why choose us

First received: June 03, 2025

Clinical Trial: Facilitators and Barriers to Eptinezumab Administration in Thailand

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Migraine

Study Type: OBSERVATIONAL


Official Title: Facilitators and Barriers to Eptinezumab Administration in Thailand: Real-World Experiences and Perspectives From Mixed-method Design and In-Depth Interviews (FACEpi)

Brief Summary: This research study is designed as a longitudinal prospective descriptive study using mixed-method data collection.Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody (anti-CGRP mAb), is administered by intravenous (IV) infusion every 3 months as preventive medication for individuals with migraine who have been diagnosed based on theInternational Classification of Headache Disorders, 3rd edition (ICHD-3) by headache specialist neurologists.The goal of this study is to understand the real-life…

Read more